Valeria Paradies

TCT-422 6 year clinical outcomes after Absorb bioresorbable scaffold implantation in small vessel: The Maasstad Absorb Registry

[2 – 3]). The PSP score displays a Nagelkerke’s R2 of 0.06, a HosmerLemeshow statistic of 3.65 (p 1⁄4 0.887), and an AUCs of 0.584 (95%CI [0.541 – 0.628]). At 1-year, a PSP score of 3 was associated with a lower rate of PoCE when compared to score of <3 (15.3% vs. 23.9%; HR 1.74, CI95% [1.27 – 2.38]; p 1⁄4 0.001), even after adjustment (HR 1.77, CI95% [1.22 – 2.59]; p 1⁄4 0.002). At 1-year, each point in the PSP score was associated with a reduction of 43% of risk of definite/probable scaffold thrombosis (HR 0.57, 95%CI [0.35 – 0.93]; p 1⁄4 0.025).

Coronary artery aneurysm after sequential stenting with bioresorbable vascular scaffolds

We report the case of a previously healthy 49-year-old woman who was referred to our cath lab for ACS NSTEMI and underwent a percutaneous coronary intervention (PCI) with a bioabsorbable vascular scaffold (BVS) on the right coronary artery (RCA) (Fig. 1a–c). Subsequent fractional flow reserve on the right posterolateral artery (RPL) showed the absence of persistent ischemia. Angiographic and optimal coherence tomography (OCT) evaluation performed 9 months later for stable angina (CCS III) indicated that a significant stenosis of the RPL ostium treated with a new BVS implantation on the RPL accidentally turned out in a ‘staged’ culotte stenting technique over the bifurcation RPL/right descending posterior artery (Fig. 1d). OCT final evaluation confirmed good apposition and expansion of the overlapped scaffolds and the mid-RCA was treated successfully with two BVSs. Final angiography showed no residual stenosis of both the lesions treated (Fig. 1e). Unfortunately, 25 months after the index procedure and 16 months after re-PCI, the patient was readmitted to our hospital for unstable angina. Angiographic

Long-term invasive follow-up of bioresorbable vascular scaffold: Optical Coherence Tomography assessment of jailed side branches

BACKGROUND Little is known about the long term development of the tissue bridges covering the struts of bioresorbable vascular scaffold (BVS) at the side branches (SB) ostium. This study aims at assessing the resorption process of jailed SB after BVS implantation. METHODS We performed both Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) analysis of 7 patients enrolled in the ABSORB Cohort B trial at our center. Orifice SB area and mean thickness of tissue bridge covering SB were calculated from 2D assessment. The number of SB orifice compartments separated by BRS struts was analysed by using 3D OCT reconstruction. RESULTS At 5years follow-up, no struts could be identified. Between 3 and 5years, both lesion-level and cross section-level OCT findings showed a significant increase in Mean lumen area (MLA) (4.67±1.66mm2 vs. 5.57±1.57mm2; p=0.04) as well as Minimum Lumen Area (MinLA) (5.98±1.98mm2 vs. 6.73±1.87mm2; p=0.04). Moreover, eccentricity index showed a significant reduction between 3 and 5years (0.28±0.35mm2 vs. 0.16±0.06mm2; p=0.04). We identified a total of 3 SBs ostia in the segments treated with BVS. Between 3 and 5years follow-up in all SB analysed, we detected a decrease of mean tissue bridge thickness and an increase of calculated SBs area. CONCLUSIONS In our serial OCT, a significant decrease of tissue bridge formation together with SB orifice area enlargement from 3 to 5year follow-up has been proved.

TCT-472 Comparison biolimus- and everolimus-eluting stents in patients with complex lesions. Five year follow-up from the COMPARE II trial

TCT-470 Two Year Clinical Results after Deployment of the Abluminal Sirolimus Coated Bio-Engineered (COMBO) Stent in a Thousand Patient All-Comers Registry Deborah Kalkman, Pier Woudstra, Peter Den Heijer, Ian Brian Alexander Menown, Andrejs Erglis, Harry Suryapranata, Karin Arkenbout, Andres Iñiguez, Arnoud van’t Hof, Philippe Muller, Jan Tijssen, Robbert de Winter Academic Medical Center, Amsterdam, Netherlands; CVPath, Gaithersburg, Netherlands; Amphia Hospital Breda, Breda, Netherlands; Craigavon Cardiac Centre, Craigavon, Northern Ireland, United Kingdom; P. Stradins Clinical University Hospital, Riga, Latvia; Zwolle, Netherlands; Ter Gooi Hospitals, Ouderkerk Amstel, Netherlands; Hosp. Álvaro Cunqueiro, Vigo, Spain; Isala, Zwolle, Zwolle, Netherlands; INCCI, Luxembourg, Luxembourg; AMC-UVA, Naarden, Netherlands; Department of Cardiology, Aarhus University Hospital, Skejby Hospital, Aarhus, Denmark

TCT-264 Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes. 5 years follow-up from the COMPARE II trial.

TCT-263 Impact of Diabetes on Clinical Outcomes in Patients Undergoing Unprotected Left Main Percutaneous Coronary Intervention with Drug-Eluting Stents Bo Xu, Jonathan Murphy, Yuejin Yang, Shubin Qiao, Changdong Guan, Runlin Gao, Ajay Kirtane Fu Wai Hospital, Beijing, Beijing, China; department of medicine, Herning hospital, denmark, new york, New York, United States; Cardiovascular Institute and Fu Wai Hospital, Beijing, Beijing, China; Beijing Fuwai Hospital, Beijing, Beijing, China; Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, Beijing, China; Fu Wai Hospital, Beijing, Beijing, China; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States

TCT-161 5 years follow-up of biolimus eluting stents versus everolimus eluting in ST-segment elevation myocardial infarction presenting patients: Results from Compare II trial

RESULTS A total of 1119 confirmed STEMI patients (51.7%) were admitted during OFF-hours and 1048 (48.3%) patients during ONhours. Baseline characteristics were well balanced between the two groups including features of high risk STEMI such as cardiac arrest (8.9% vs. 7.9% p 1⁄40.55) and shock (14.7% vs. 12.3 % p1⁄4 0.30). Time from symptom onset to First Medical Contact (FMC) and from FMC to angiography were similar during OFF-hours and ON-hours (120 min p1⁄40.67 and 94 min p1⁄40.2). The use of radial access was high and not different (87.5 % and 88.4 %, p1⁄40.27) in OFFvs. ON-hours. In-Hospital mortality during OFFvs. ON-hours was 1.6 % vs. 2.8% in patients without cardiac arrest or shock (p1⁄40.14) and 45.1 % vs. 50.4% (p1⁄40.39) in those with cardiac arrest or shock. At one-year follow-up, there was no impact of admission time on all-cause mortality (12% vs. 13.4%, p1⁄40.40).

TCT-467 Comparison biolimus- and everolimus-eluting stents in patients with small vessels disease. Five year follow-up from the COMPARE II trial

Drug eluting stents with biodegradable polymer have been developed to address the risk of very late adverse events. COMPARE II is one of the largest randomized studies comparing the biodegradable polymer-coated biolimus-eluting stent (BES; Nobori®) with second-generation durable polymer-coated